Abcam, ab263324, Human QTRT1 knockout HeLa cell lysate

Size: 1Kit
QTRT1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon 1 and 46 bp deletion in exon 1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon 1 and 46 bp deletion in exon 1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-QTRT1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The TGT protein also known as tRNA-guanine transglycosylase functions mechanically by modifying transfer RNA (tRNA) molecules through the exchange of guanine at specific tRNA positions with preQ1 precursors. This enzymatic activity is essential in tRNA maturation. The enzyme has a molecular mass of about 43 kDa. TGT is expressed mainly in the cytoplasm of eukaryotic cells and shows a high level of conservation across different species.
Biological function summary
The TGT catalyzed guanine exchange on tRNA enhances the correct folding of tRNA and supports the accuracy of protein translation. The protein is a part of an RNA-modifying enzyme family and does not typically form complexes but acts independently on its tRNA substrates. Its activity ensures proper tRNA structure influencing protein synthesis efficiency and overall cellular protein homeostasis.
Pathways
TGT plays an important role in the tRNA modification pathway which is important for post-transcriptional RNA processing. It connects with pathways involved in protein synthesis and RNA stability. TGT's function is integrally linked with enzymes like tRNA synthetases which are responsible for charging tRNAs with their corresponding amino acids establishing a pivotal link in the genetic code translation process.
Alterations in TGT function or expression impact specific disorders such as mitochondrial myopathy which results from defects in tRNA modification leading to flawed mitochondrial protein synthesis. TGT also has connections to cancer biology where aberrant tRNA modifications by TGT might influence tumoral cell growth and response to stress. In these contexts the interactions between TGT and other proteins involved in RNA metabolism such as Dicer point to a broader influence on cellular regulatory mechanisms linked to disease states.